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HIV-1 protease (PR) is a 99 amino acid protein responsible for proteolytic processing of the viral polyprotein
– an essential step in the HIV-1 life cycle. Drug resistance mutations in PR that are selected during anti-
retroviral therapy lead to reduced efﬁcacy of protease inhibitors (PI) including darunavir (DRV). To identify
the structural mechanisms associated with the DRV resistance mutation L33F, we performed X-ray crystal-
lographic studies with a multi-drug resistant HIV-1 protease isolate that contains the L33F mutation
(MDR769 L33F). In contrast to other PR L33F DRV complexes, the structure of MDR769 L33F complexed with
DRV reported here displays the protease ﬂaps in an open conformation. The L33F mutation increases non-
covalent interactions in the hydrophobic pocket of the PR compared to the wild-type (WT) structure. As a
result, L33F appears to act as a molecular anchor, reducing the ﬂexibility of the 30s loop (residues 29–35) and
the 80s loop (residues 79–84). Molecular anchoring of the 30s and 80s loops leaves an open S1/S1′ subsite
and distorts the conserved hydrogen-bonding network of DRV. These ﬁndings are consistent with previous
reports despite structural differences with regards to ﬂap conformation.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The current standard of care for HIV, HAART, often employs a
protease inhibitor (PI) containing regimen [1] but mutations in HIV-1
protease (PR) that develop in treatment-experienced patients
decrease the efﬁcacy of all current PIs including DRV [1, 2, 3]. Thus,
further analysis of key HIV-1 protease resistance mutations is needed
to develop more potent antivirals to combat drug resistance.
Clinical isolates previously obtained from the Wayne State
University Infectious Disease Clinic in Detroit, MI contain major
drug resistance mutations L33F, I47V, I50V, I54M, L76V, V82I/F,
and I84F as well as nonpolymorphicaccessory mutations L10V/G,
V11I, I13V, K20T/R, L33I/M, K43T, F53L, A71L, T74P, and L89V.
These mutations confer resistance to all FDA approved PIs (http://an open access article under the C




.hivdb.stanford.edu/) [4]. Molecular dynamics simulations with
these isolates showed altered PR ﬂap dynamics [5].
To further investigate the role of the L33F mutation, we created a
recombinant MDR769 L33F PR and performed X-ray crystallographic
studies. L33F was initially identiﬁed as an accessory mutation to I54L/
M, V32Iþ I47V, and I84V/I but is now recognized as a non-
polymorphic major drug resistance mutation [4,6]. L33F is selected
for in patients on a ritonavir pharmacokinetic boosted darunavir
(DRV/r) regimen [3], is associated with DRV/r resistance [7], has
greatly increased in prevalence since the year 2000 [8], and has di-
rect inﬂuence on inhibitor-interacting residues [9]. We hypothesize
that reduced ﬂexibility of the 30s and 80s loops due to molecular
anchoring properties of L33F may contribute to drug resistance.2. Materials and methods
2.1. Protein expression, puriﬁcation, and crystallization
The recombinant MDR769 L33F HIV-1 protease was expressed
using a T7 promoter expression vector with Escherichia coli BL21C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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multi-drug resistant variant 769, MDR769, which contains the
mutations Q7K, L10I, M36V, M46L, I54V, I62V, L63P, A71V, V82T,
I84V, L90M [10]. MDR769 L33F contains all mutations seen in
MDR769 as well as the additional mutation L33F. Puriﬁcation
strategies were carried out as previously described [11,12]. Apo
MDR769 L33F was crystallized using the hanging-drop vapor dif-
fusion method. Two precipitant conditions produced crystals:
(2.4 M ammonium sulfate, 0.1 M MES, pH 6.2) and (2.4 M ammo-
nium sulfate, 0.1 M HEPES, pH 6.8). Co-crystallization methods
were unable to produce high-quality crystals; therefore, apo
crystals were soaked for 19 h in conditions matching the mother
liquor in which they were formed, with the addition of DRV in
molar excess (5 mM DRV, 5% DMSO). The crystals were cryopro-
tected with 30% glucose and were ﬂash frozen in liquid nitrogen.
Data were collected at the LS-CAT facility, located within Argonne
National Laboratory's Advanced Photon Source.2.2. Structure determination, reﬁnement, and analysis
The structure of the apo L33F model was determined at a re-
solution of 1.50 Å. It was phased by molecular replacement (MR)
using PHASER [13] with PDB entry 1TW7 as the initial search
model. Reﬁnement was performed using Phenix [14]. Subsequent
structures containing a PI were phased using the apo L33F struc-
ture as a search model. The models were built in COOT [15]. After
MR, ligands were added manually into the model after the protein
was reﬁned. A round of reﬁnement was performed with PDB-
REDO [16] before deposition to the protein data bank (www.pdb.
org). The ﬁnal models were analyzed and validated with Mol-
Probity [17]. All images were created using PyMoL [18]. Non-
covalent interactions were identiﬁed using LigPlotþ [19]. Hydro-
gen bonds were identiﬁed as donor–acceptor pairs with a cutoff
distance of 3.2 Å; all distances were measured in PyMoL. The
crystallographic data are shown in Supplementary material.Fig. 1. Structural features of the residue 33 molecular anchor. (A) Superposition of WT p
apo structures. The 30s loop, which contains residue 33, is positioned between the 80s lo
are shown, respectively. Color schemes for (B–D) are as shown in (A). L33F ﬁlls the hydr
map for MDR769 L33F contoured at 1s.2.3. Molecular dynamics simulations
Coordinates for wild-type PR [20] (3PHV.pdb), MDR769 [10]
(1TW7.pdb), and MDR769 L33F (4YOB.pdb) were used for system
preparation. Crystallographic waters were retained during the
initial setup. The biologically active homodimer of the protease
was used for the simulations. The systems were placed in a TIP3P
5 Å water box and neutralized with magnesium chloride. MD si-
mulations were performed as previously described [5] using
NAMD [21] V. 2.9.
Trajectories of the MD simulation were analyzed using Visual
Molecular Dynamics [22] (VMD) V. 1.92. Residue RMSD values
were calculated using the Timeline tool in VMD by analysis of the
last 10 ns of the simulation utilizing the frame corresponding to
30 ns as the reference frame.3. Results
3.1. Structural features of the residue 33 environment
The side chain of L33F extends 2.2 Å deeper into the hydro-
phobic pocket compared to wild-type (WT) L33 (Fig. 1) leading to
increased hydrophobic interactions between L33F and the hydro-
phobic pocket. The hydrophobic pocket is deﬁned by residues I13,
I15, K20, A22, T31, M/V36, L38, I64, I66, V75, V77, N83, and I85
(Fig. 1B–D). To visually identify changes in these residues, we
aligned and superimposed the WT, MDR769, and MDR769 L33F
structures. Although conformational and positional changes in
these residues are seen between the WT and MDR769 structures
(Fig. 1B and C), the L33F mutation produces further alterations in
many of these residues (Fig. 1D). The most notable change is in
residue I13, which rotates to avoid steric clashes with L33F. Other
signiﬁcant changes due to the L33F mutation are noted in residues
I15, K20, A22, V36, L38, I66, and N83. These changes lead to in-
creased hydrophobic interactions in L33F compared to the WT and
MDR769 structures (Table 1).rotease (green), MDR769 protease (magenta), and MDR769 L33F protease (yellow)
op and the hydrophobic pocket. In (B), (C) and (D) WT, MDR769, and MDR769 L33F
ophobic pocket more completely than L33. The inset in panel (D) shows the 2Fo– Fc
Table 1
Top row: non-covalent interactions between residue 33 (L/F) and hydrophobic pocket residues. Bottom row: non-covalent interactions between DRV and active site residues.
Interactions involving residue 33L/F were identiﬁed using the DimPlot script in LigPlotþ; interactions between PR and DRV in the complexed structures were determined
using LigPlotþ . Mutations present in MDR769 reduce the number of non-covalent interactions with the hydrophobic pocket. Substitution of L33F restores the interactions
between residue 33 and the hydrophobic pocket and extends them beyond what is observed in the WT structures. Interactions between DRV and the active site are reduced
by mutations present in MDR769 but are further reduced due to the molecular anchoring properties of the non-polymorphic L33F mutation.
Structure name WT apo WT:DRV complex MDR769 apo MDR769:DRV MDR769 33F apo MDR769 33F:DRV complex
PDB code 3PHV 4LL3 1TW7 3SO9 4YOB 4YOA
Residue 33L/F non-covalent interactions 30 27 24 23 32 31
DRV:non-covalent interactions N/A 63 N/A 53 N/A 34
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to the WT and MDR769 structures. Upon drug binding, L33 in the
WT–DRV complex shifts 1.1 Å towards the active site and a hy-
drogen bond is formed between the backbone amide nitrogen of
L33 and the backbone carbonyl of G78. Additionally, the side
chains of residues I13, I15, M36, I66, and V75 are rotated, residues
I15, K20, M36, L38, and V77 shift 0.4 Å, 1.2 Å, 2.3 Å, and 2.1 Å, re-
spectively, into the hydrophobic pocket, and residues T31, V75,
N83, and I85 shift 0.8 Å, 0.7 Å, 1.0 Å, and 0.5 Å away from the
pocket. Similar changes occur in the MDR769 structures upon drug
binding. However, with the L33F mutation, minimal changes in
conformation or position occur in either L33F or residues of the
hydrophobic pocket upon drug binding in the MDR769 L33F
structure.
3.2. L33F as a molecular anchor
When the 30s loop (residues 29–35) of PR bears the L33F muta-
tion, ﬂexibility of both the 30s and 80s loops (residues 79–84) is
decreased, likely through increased hydrophobic interactions. The 80s
loop inﬂuences the S1/S1′ binding site [23], and the 30s loop lies
between the 80s loop and the hydrophobic pocket (Fig. 1A). In theFig. 2. L33F acts as a molecular anchor that restricts movement of the 30s and 80s lo
(B) Superposition of MDR769 apo (magenta) and MDR769–DRV complex (blue). The 30
MDR769 33F apo (yellow) and MDR769 L33F–DRV complex (red). L33F prevents move
structures. The inset in (C) shows the 2Fo– Fc map for the 30s loop residues (D29–E35)WT–DRV complex, drug binding causes the 30s loop residues to shift,
on average, 1.5 Å towards the active site compared to the WT apo
structure (Fig. 2A). In a similar fashion, the adjacent 80s loop residues
also shift, on average, 2.0 Å towards the active site (Fig. 2A). Fur-
thermore, residue 33L in the WT–DRV complex displays fewer non-
covalent interactions compared to the WT apo structure (Table 1).
Similar to the WT–DRV complex, the 30s and 80s loops of the
MDR769–DRV complex shift 1.6 Å and 2.4 Å, respectively, towards the
active site compared to the apo structure (Fig. 2B). Also, the number
of noncovalent interactions is severely reduced in the MDR769
structures compared to the WT structures (Table 1). However, the 30s
and 80s loops of the MDR769 L33F–DRV complex show minimal
shifting upon drug binding; the only signiﬁcant change is in residue
P81, which shifts 0.4 Å into to the active site and puckers up when
DRV is bound in the active site (Fig. 2C). In addition to the decreased
ﬂexibility of the 30s and 80s loops in the MDR769 L33F structures, the
L33F mutation restores the noncovalent interactions with the hy-
drophobic pocket that were originally lost in the MDR769 complex.
These restored interactions are also more extensively maintained than
in the WT–DRV complex (Table 1). The decreased ﬂexibility of both
the 30s and 80s loops is likely due to enhanced anchoring by L33F via
increased hydrophobic interactions within the hydrophobic pocket.ops. (A) Superposition of WT apo protease (green) and WT–DRV complex (cyan).
s loop and 80s loop in (A) and (B) both shift with DRV bound. (C) Superposition of
ment of the 30s and 80s loops towards the active site as in the WT and MDR769
contoured at 1s.
Fig. 3. Reduced ﬂap interactions due to L33F anchoring. (A) WT apo protease and WT protease complexed with DRV. The apo WT shows a 7.5 Å gap between P81 of the 80s
loop and I50 of the ﬂap producing an active site in the open conformation. When complexed with DRV, the ﬂaps and active site close. (B) MDR769 apo protease and
MDR769–DRV complex. Despite interactions between the 80s loop and ﬂaps in the MDR769 protease, the ﬂaps and active site display an open conformation. With DRV in the
active site, the ﬂexibility of MDR769 protease produces a closed active site. (C) MDR769 L33F apo PR and MDR769 L33F complexed with DRV bound resembles the WT apo
structure in (A) with a large gap between residues I50′ and P81. The gap between I50′ and P81 is maintained between the apo and complexed structures (5.8 Å and 5.9 Å,
respectively) and is too large for interactions to occur. The active site and S1/S1′ subsite remain open. The inset in (C) shows the 2Fo– Fc map for DRV and the 80s loop in the
L33F structure contoured at 0.5s in order that the density around DRV is shown.
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anchor, 40 ns MD simulations were performed. Differences in
protein ﬂexibility due to molecular anchoring of L33F should be
more pronounced in apo PR compared to PI-complexed forms.
Therefore the RMSD of the 30s and 80s loops for both chains of
apo WT, MDR769, and MDR769 L33F were analyzed over the last
10 ns. For WT PR, the average RMSD values of the 30s and 80s
loops were 1.53 Å and 1.65 Å, respectively. The 30s loop of the
MDR769 structure showed reduced ﬂexibility compared to the WT
structure with an RMSD of 1.34 Å whereas the 80s loop of the
MDR769 showed similar ﬂexibility compared to the WT (1.66 Å).
Flexibility of the 30s and 80s loops in MDR769 L33F were further
reduced compared to both WT and MDR769 structures with the
30s loop displaying an RMSD of 1.27 Å and the 80s loop displaying
an RMSD of 1.55 Å (Fig. S1).
3.3. Reduced ﬂap interactions and altered drug conformation
Previous work documented interactions between the 80s loop
and the ﬂap tips [24], their importance in substrate recognition
and binding [25], and their inﬂuence on forming the S1/S1′ subsite
[23]. Thus, effects of the L33F mutation on the 80s loop and ﬂap
tips are possibly implicated in resistance development.
In the WT protease, the ﬂexibility of the 80s loop and ﬂaps
produces favorable interactions allowing for proper formation of
the S1/S1′ subsite. In the WT apo structure, a large 7.5 Å gap be-
tween the P81 of the 80s loop and I50 of the ﬂap tips exists,
preventing any interactions between the two (Fig. 3A). However,
with DRV bound in the active site, the ﬂaps close and the 80s loop
shifts (2.0 Å) towards the active site which brings P81 within 3.7 Å
of G49′ and T80 within 3.9 Å of I50′ (Fig. 3A). These distances al-
low for favorable interactions between the ﬂap and the 80s loop
resulting in a closed active site, and more speciﬁcally, a properly
formed S1/S1′ subsite (Fig. 3A). As a result, DRV makes extensive
noncovalent interactions with the residues lining the active site as
indicated in Table 1.
Similar to the WT protease, the MDR769 protease displays
considerable ﬂexibility in the 30s and 80s loops (Fig. 3B). The gap
between residues P81 and I50′ in the MDR apo structure is not
large compared to the WT (3.6 Å compared to 7.5 Å). The ﬂaps are
in a “wide-open” conformation as reported previously [10], which
leaves the active site open. In the MDR769–DRV complex, the
ﬂexibility of the 30s and 80s loops (Fig. 2B) allows the active site to
close (Fig. 3B). Even though the active site is closed, the number of
noncovalent interactions between DRV and the active site is de-
creased, suggesting a slightly distorted active site (Table 1).
In the MDR769 L33F apo structure, the gap between the 80s
loop and the ﬂaps resembles the WT apo structure, producing an
open active site and an open S1/S1′ subsite. The apo structure
contains a 5.8 Å gap between P81 and I50′; this gap is smaller than
the WT but still too large for any signiﬁcant interactions to occur.
In the L33F–DRV complex, P81 shifts 0.4 Å into the active site, but
I50′ also shifts and rotates leaving a 5.9 Å gap which resembles the
WT apo structure (Fig. 3C). The 5.9 Å gap between P81 and I50′
leaves an open S1/S1′ subsite and also results in an open active
site. The result is a severely reduced number of interactions be-
tween DRV and the active site compared to both the WT and
MDR769 structures (Table 1).
Additionally, in the L33F–DRV complex, the side chains of P2,
P1, and P1′ of DRV are rotated to compensate for the open S1/S1′
subsite (Fig. 3C) which alters the hydrogen-bonding network
compared to the WT–DRV complex. Previous reports have in-
dicated a conserved hydrogen bonding network between DRV and
backbone and side-chain atoms of residues D25, G27, D29, D30,
D25′, and D30′ [26]. In the WT–DRV complex, the P2 bis-THF
moiety, hydroxyl, and P2′ amine of DRV are responsible forformation of ﬁve hydrogen bonds with residues D25, D29, D30,
D25′, and D30′ (data not shown). However, the L33F–DRV complex
contains an expanded active site and S1/S1′ subsite which alters
the conformation of P2, P1, P1′, and P2′ of DRV. As a result, the P2
bis-THF moiety, hydroxyl, and P2′ amine of DRV form only three
hydrogen bonds with residues D25N, D30, and D29′. Additionally,
the number of contacts decreased between the P1 group of DRV
and the residues of the S1/S1′ subsite (Table 1).4. Discussion
The L33F mutation is selected in patients receiving a DRV/r
regimen [3], and is associated with reduced response to DRV/r
treatment [4,7] as it has direct inﬂuence on the inhibitor-inter-
acting residues [9]. This report describes the effects of L33F on the
structure of HIV protease as well as the effect it has on inhibitor
recognition.
Superposition of MDR769 L33F with WT and MDR769 HIV-1 PR
with and without DRV in the active site reveals altered con-
formation of the 30s and 80s loops. The larger side chain of L33F
embeds further into the hydrophobic pocket than L33, the latter of
which is present in both WT and MDR769 structures (Fig. 1). As a
result, noncovalent interactions are increased in this region com-
pared to the WT, causing the L33F to act as a molecular anchor. MD
simulations showed a clear reduction in ﬂexibility of both the 30s
and 80s loops for MDR769 L33F compared to both WT and
MDR769. The results of these simulations support the hypothesis
that L33F may play a role as a molecular anchor within HIV-1
protease.
Enhanced molecular anchoring by the L33F mutation reduces
the ﬂexibility of the 30s and 80s loops, thereby inhibiting proper
formation of the S1/S1′ subsite and keeping the active site in an
open conformation in the MDR769 L33F–DRV complex (Figs. 2
and 3). Conversely, in the WT and MDR769 complex structures,
DRV binding causes a shift in the 30s and 80s loops leading to
formation of the S1/S1′ subsite and closing of the active site
(Figs. 2 and 3).
The structure of the L33F DRV complex reported here shows
the protease ﬂaps in an open conformation. To date, all deposited
structures of HIV PR L33F complexes have been solved in three
different space groups: P212121, P61, and P41212. The majority of
these HIV PR L33F DRV complexes have been solved with the ﬂaps
in a closed conformation. Other research groups such as the
Schiffer group [27] and the Konvalinka group [28] have previously
reported L33F DRV complexes with the ﬂaps in a closed con-
formation by solving the structures in P212121 (PDB ID:4QY1) and
P61 (PDB ID:3GGU), respectively. In contrast, the Weber group [29]
and this report describe the L33F DRV complex as a structure with
open protease ﬂaps when the structures were solved in P41212.
The Weber group [29] (PDB ID:4NPT) also utilized the inactivating
mutation D25N to facilitate HIV PR expression, puriﬁcation, and
crystallization.
With speciﬁc regard to the L33F mutation, the Schiffer group
(closed protease ﬂaps) reports L33F may play a role in active site
expansion [27]. The Konvalinka group (closed protease ﬂaps)
suggests that L33F is possibly implicated in structural changes in
the ﬂap and ﬂap hinge regions of PR. Despite structural and
symmetry differences between the aforementioned and this re-
port, our results regarding L33F as a molecular anchor are con-
sistent with the previous reports by the the Schiffer and Konva-
linka groups. A key ﬁnding of our report is the inﬂuence of the
L33F mutation on the open active site and on the S1/S1′ subsites
through anchoring of the 30s and 80s loops independent of space
group.
B.D. Kuiper et al. / Biochemistry and Biophysics Reports 2 (2015) 160–165 165In conclusion, for the ﬁrst time we here report the molecular
mechanisms by which the nonpolymorphic PR mutation L33F
contributes to DRV resistance. The L33F mutation may contribute
to resistance via two mechanisms: one, by restoring noncovalent
interactions lost due to other primary mutations, and two, by
further reducing interactions between DRV and active site re-
sidues. These ﬁndings may contribute to our overall understanding
of drug resistance as well as future drug design strategies. We
propose that modiﬁcations to the P1/P1′ groups of existing PIs to
ﬁll the open S1/S1′ subsite might result in a greater response by
patients who harbor the L33F mutation in HIV-PR.Acknowledgments
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